S. Blanch

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

A. Prat, B. Adamo, P. Villagrasa, 2019, Breast Cancer Research.

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

S. Servitja, A. Llombart-Cussac, J. Cortés, 2022, Neuro-oncology.

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

J. Gavilá, M. Atienza, E. Aguirre, 2023, Clinical and Translational Oncology.

Abstract PD4-06: Trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study

S. Servitja, A. Llombart-Cussac, J. Cortés, 2022, Cancer Research.

Abstract PS12-08: A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1)

M. Juan, G. Nuovo, M. Coffey, 2021 .

Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

S. Servitja, R. Andrés, A. Llombart-Cussac, 2020, Breast.

Abstract PD7-02: Trastuzumab Deruxtecan in patients with Unstable Central Nervous System Involvement from HER2-Low Advanced Breast Cancer: The DEBBRAH Trial

S. Servitja, A. Llombart-Cussac, J. Cortés, 2023, Cancer Research.